State Street SPDR S&P Pharmaceuticals ETF
XPH
73 hedge funds and large institutions have $108M invested in State Street SPDR S&P Pharmaceuticals ETF in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
11% more funds holding
Funds holding: 66 → 73 (+7)
0.6% less ownership
Funds ownership: 53.38% → 52.78% (-0.6%)
2% less capital invested
Capital invested by funds: $111M → $108M (-$2.45M)
13% less call options, than puts
Call options by funds: $901K | Put options by funds: $1.04M
21% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$5.44M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$3.04M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.87M |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$13.8M |
| 2 |
Morgan Stanley
New York
|
-$5.77M |
| 3 |
CI
CX Institutional
Auburn,
Indiana
|
-$3.17M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.14M |
| 5 |
LPL Financial
San Diego,
California
|
-$755K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FTUS
76
Flow Traders U.S.
New York
| – | -$719K | -17,895 | Closed |
|
|
TRCT
77
Tower Research Capital (TRC)
New York
| – | -$286K | -7,134 | Closed |
|
|
EW
78
Evoke Wealth
Los Angeles,
California
| – | -$129K | -3,200 | Closed |
|
79
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$74K | -1,845 | Closed |
|
|
HI
80
Harbour Investments
Madison,
Wisconsin
| – | -$20K | -485 | Closed |
|
|
SWA
81
Sutton Wealth Advisors
Tampa,
Florida
| – | -$5.54K | -138 | Closed |
|
|
FRA
82
Front Row Advisors
Tiburon,
California
| – | -$1.87K | -45 | Closed |
|
|
PTC
83
Private Trust Company
Cleveland,
Ohio
| – | -$1K | -31 | Closed |
|
84
Simplex Trading
Chicago,
Illinois
| – | +$416 | +10 | New |
|
XPH Hedge Fund Activity: Q4 2022 in Review
73 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2022, worth a combined $108M — down 2.2% from $111M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new XPH positions and 10 closed out — a net gain of 8 holders — while 15 added to existing stakes and 19 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $5.44M. The largest seller was Raymond James Financial Services Advisors, cutting an estimated $13.8M.
- 73 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2022, up from 66 in Q3 2022.
- Funds reported $108M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2022, down 2.2% quarter-over-quarter.
- 18 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2022 and 10 closed out, a net change of +8 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2022 was Goldman Sachs, an estimated $5.44M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2022 was Raymond James Financial Services Advisors, an estimated $13.8M sold.
Based on aggregated 13F filings for Q4 2022.